Medical News

RSS

Asparity extends free usage period for PlanSmartChoice online tool for federal employees

Asparity Decision Solutions is pleased to announce that www.PlanSmartChoice.com will continue to be available free to all federal employees during the 2010 open season, which begins November 9, 2009.

3 Sep 2009

Jedi Mind to develop medical applications for patients in wheelchairs

Jedi Mind, Inc. (Pink Sheets: JEDM) (http://www.jedimindinc.com) announced today that their Medical Division is now working on a number of medical applications for patients in wheelchairs.

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Sinovac Biotech signs marketing agreement with Boryung Pharmaceutical Company

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has signed an agreement with Boryung Pharmaceutical Company Limited, a Korean manufacturer of pharmaceuticals, to collaborate on marketing efforts and possible vaccine supply efforts to the government of South Korea for Sinovac's H1N1 vaccine.

3 Sep 2009

ASGE Endoscopy Unit Recognition Program identifies 10 endoscopy units to promote quality care

The American Society for Gastrointestinal Endoscopy (ASGE) has recognized 10 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States. The ASGE Endoscopy Unit Recognition Program honors endoscopy units that follow the ASGE guidelines on privileging, quality assurance, endoscopy reprocessing and CDC infection control guidelines. To date, 134 endoscopy units have been recognized by ASGE.

3 Sep 2009

IDEAL IMPLANT clinical trial features lump-sum payment to participants

A clinical trial of the IDEAL IMPLANT Saline-filled Breast Implant offered Teri a new “hybrid” design, combining both the natural result of silicone gel with the safety of saline for peace of mind. The trial also features a unique lump-sum payment to participants from a trust fund.

3 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Bio-Reference Laboratories reports third-quarter fiscal 2009 revenues

Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $97,424, the best ever quarter in terms of revenues in corporate history and an increase of more than 25% over the $77,776 recorded in the third quarter, fiscal year 2008.

3 Sep 2009

Gross sales of EFT BioTech Holdings crosses $100 million

EFT BioTech Holdings, Inc. (PINKSHEETS: EFTB), a business to consumer, on line marketing Company providing "Made in the USA" health, beauty, nutriceutical products along with other goods and services under the EFT brand to its affiliate member network, boasting almost one million registered members strong, reports surpassing $100 million in gross sales since its public listing in November 2007.

3 Sep 2009

Rural states with much to gain under reform also feature most vocal opponents

The Los Angeles Times reports: "Some of the most vociferous opposition to the proposals before the House and Senate comes from residents of rural states that could benefit most if the present system is revamped.

3 Sep 2009

New clinical trials to address the effectiveness of antimicrobial drugs

Scientists are addressing the threat of antimicrobial drug resistance by launching two new clinical trials aimed at prolonging the effectiveness of currently available antibacterial drugs. The concept underlying both studies: Less is more.

3 Sep 2009

Implanet to use IBM's sensor technology for its new implant device tracking service

Implanet, a manufacturer of implantable medical devices, has selected IBM (NYSE: IBM) sensor technology as the foundation for BeepN'Track, a new service that traces the movement of Implanet's products - including knee and hip implants - across its supply chain to hospitals.

3 Sep 2009

Tucson Orthopaedic Institute chooses CoreTrace's BOUNCER endpoint system protection solution

CoreTrace, the pioneer of client-based application whitelisting technology, today announced that Tucson Orthopaedic Institute, one of the largest orthopaedic groups in the United States, has selected CoreTrace's award-winning BOUNCER solution for endpoint protection of its systems located throughout the Institute's eight centers.

3 Sep 2009

Clinical trial results of sumatriptan published in a journal

NovaDel Pharma Inc. announced that an article titled “Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine” was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain.

3 Sep 2009

Swine flu prevention kits launched

MisterSterile.com have launched a unique range of swine flu prevention kits for the home, office, school, hospital, travel & personal use.

3 Sep 2009

Mosquito screens prevent malaria

Trials of a screen-based malaria prevention programme in 500 homes in The Gambia, Africa, have led to a 50 per cent reduction in malaria transmission and anaemia in children. A child dies from malaria in Africa every 30 seconds and infection can lead to an increased risk of anaemia, which can also prove fatal. Yet to date, screens have often been ignored in favour of using drugs and insecticides.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

Novel oncology therapeutic evaluation in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

3 Sep 2009

Gene-Eden antiviral supplement may offer protection against swine flu

Everyone is looking for ways to protect themselves against the swine flu virus. Let me tell you about my personal encounter with the virus. About three months ago, I read an article on Dr. Hanan Polansky's book, where he describes his discovery of the relationship between chronic viruses and chronic disease. After I read the article, I started taking Gene-Eden, a broad range antiviral supplement, to reduce the number of chronic viruses in my body.

3 Sep 2009

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.

3 Sep 2009